Evidence map›Paper›PMID 34831346›Full record

ArticleCells2021

L-Arginine Ameliorates Defective Autophagy in GM2 Gangliosidoses by mTOR Modulation.

Beatriz Castejón-Vega, Alejandro Rubio, Antonio J Pérez-Pulido, José L Quiles, Jon D Lane, Beatriz Fernández-Domínguez, María Begoña Cachón-González, Carmen Martín-Ruiz, Alberto Sanz, Timothy M Cox and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Genetic mutation and immune infiltration in embryonal tumor with multilayered rosettes.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 2 countries.

Beatriz Castejón-VegaResearch Laboratory, Oral Medicine Department, University of Sevilla, 41009 Sevilla, Spain.
Alejandro RubioCentro Andaluz de Biologia del Desarrollo (CABD, UPO-CSIC-JA), Facultad de Ciencias Experimentales (Área de Genética), Universidad Pablo de Olavide, 41013 Sevilla, Spain.ORCID 0000-0002-6736-6141
Antonio J Pérez-PulidoCentro Andaluz de Biologia del Desarrollo (CABD, UPO-CSIC-JA), Facultad de Ciencias Experimentales (Área de Genética), Universidad Pablo de Olavide, 41013 Sevilla, Spain.
José L QuilesDepartment of Physiology, Institute of Nutrition and Food Technology "José Mataix Verdú", Biomedical Research Center, University of Granada, 18071 Granada, Spain.ORCID 0000-0002-9048-9086
Jon D LaneCell Biology Laboratories, School of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Beatriz Fernández-DomínguezAcción y Cura Para Tay-Sachs (ACTAYS), 28220 Madrid, Spain.
María Begoña Cachón-GonzálezDepartment of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.
Carmen Martín-RuizBiosciences Institute, Newcastle University, Newcastle upon Tyne NE4 5 PL, UK.ORCID 0000-0002-3361-6974
Alberto SanzInstitute of Molecular, Cell and Systems Biology, University of Glasgow, Glasgow G12 8QQ, UK.
Timothy M CoxDepartment of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0002-4951-9941
Elísabet Alcocer-GómezDepartamento de Psicología Experimental, Facultad de Psicología, Universidad de Sevilla, 41009 Seville, Spain.
Mario D CorderoInstituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz (INiBICA), 11009 Cadiz, Spain.ORCID 0000-0003-0151-3644
Centro Andaluz de Biología del Desarrollo · ESUniversidad de Sevilla · ESUniversity of Cambridge · GBAcciona (Spain) · ESInstituto de Salud Carlos III · ESNewcastle University · GBUniversidad de Granada · ESUniversity of Bristol · GBUniversity of Glasgow · GB

Funding

Biotechnology and Biological Sciences Research Council BB/T016183/1Medical Research Council MR/K025570/1
6 · The paper itself

Abstract

aimsTay-Sachs and Sandhoff diseases (GM2 gangliosidosis) are autosomal recessive disorders of lysosomal function that cause progressive neurodegeneration in infants and young children. Impaired hydrolysis catalysed by β-hexosaminidase A (HexA) leads to the accumulation of GM2 ganglioside in neuronal lysosomes. Despite the storage phenotype, the role of autophagy and its regulation by mTOR has yet to be explored in the neuropathogenesis. Accordingly, we investigated the effects on autophagy and lysosomal integrity using skin fibroblasts obtained from patients with Tay-Sachs and Sandhoff diseases.

resultsPathological autophagosomes with impaired autophagic flux, an abnormality confirmed by electron microscopy and biochemical studies revealing the accelerated release of mature cathepsins and HexA into the cytosol, indicating increased lysosomal permeability. GM2 fibroblasts showed diminished mTOR signalling with reduced basal mTOR activity. Accordingly, provision of a positive nutrient signal by L-arginine supplementation partially restored mTOR activity and ameliorated the cytopathological abnormalities. INNOVATION: Our data provide a novel molecular mechanism underlying GM2 gangliosidosis. Impaired autophagy caused by insufficient lysosomal function might represent a new therapeutic target for these diseases.

conclusionsWe contend that the expression of autophagy/lysosome/mTOR-associated molecules may prove useful peripheral biomarkers for facile monitoring of treatment of GM2 gangliosidosis and neurodegenerative disorders that affect the lysosomal function and disrupt autophagy.

Indexed as

AutophagyArginineAutophagosomesCathepsinsFibroblastsGangliosidoses, GM2Hexosaminidase AHexosaminidase BHumansLysosomesMutationPermeabilityProto-Oncogene Proteins c-aktSandhoff DiseaseSignal TransductionTay-Sachs DiseaseArginineCathepsinsHexosaminidase AHexosaminidase BProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesautophagyGM2 gangliosidosisL-argininemTOR

Identifiers

PMID34831346
PMCPMC8619250
OpenAlexW3214597858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.